Article Details

AstraZeneca's Tagrisso gets FDA priority review in lung cancer subtype | Seeking Alpha

Retrieved on: 2023-10-16 12:30:50

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Tagrisso gets FDA priority review in lung cancer subtype | Seeking Alpha. View article details on hiswai:

Excerpt

The FDA granted priority review to AstraZeneca's (AZN) Tagrisso combo to treat certain patients with a type of lung cancer. Read more here.

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up